Indication
As monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Medicine details
- Medicine name:
- teclistamab (Tecvayli)
- SMC ID:
- SMC2668
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 09 September 2024
- SMC meeting date:
- 06 August 2024
- Patient group submission deadline:
- 03 June 2024